search
Back to results

Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

Primary Purpose

Rheumatoid Arthritis

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Hematopoietic Stem Cell Transplantation
Fludarabine
Cyclophosphamide
Campath 1H
GCSF
Cyclosporins
Mycophenolate Mofetil
Sponsored by
Northwestern University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rheumatoid Arthritis

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Participant Inclusion Criteria: Age > 18 and < 60 years at time of pre-transplant evaluation. An established clinical diagnosis of rheumatoid arthritis by American College of Rheumatology criteria. Patients must have failed an autologous hematopoietic transplant or have failed to respond to either methotrexate or leflunomide in combination with a TNF inhibitor. Failure is defined as an inability to tolerate treatment with at least 6 swollen joints and 20 involved joints or inability to answer at least 70% of HAQ questions with "no difficulty" despite 2 or more months of treatment. Ability to give informed consent. Patient must have a HLA matched sibling donor at the A, B, C, and DR loci to proceed or HLA matched cord blood donor. If donor is HLA matched cord blood, cord blood stem cells will be obtained from the NMDP (1-800-548-1375) and one or two units of HLA matched cord blood will be infused on day zero. Participant Exclusion Criteria History of coronary artery disease, or documented congestive heart failure. HIV positive. Uncontrolled diabetes mellitus, or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemoradiotherapy. Prior history of malignancy except localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage I breast cancer will be considered on an individual basis. Positive pregnancy test, inability or unwillingness to pursue effective means of birth control, failure to willingly accept or comprehend irreversible sterility as a side effect of therapy. Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible. FEV1/FVC < 70% of predicted, DLCO < 40% of predicted. Resting LVEF < 45 %. Bilirubin > 2.0 mg/dl (unless due to Gilberts), transferase (AST) > 2.5 x upper limit of normal. Serum creatinine > 2.0 mg/dl. Donor Exclusion Criteria Age < 18 years. Positive for HIV-1, HIV-2, HTLV-I, HTLV-II. Active hepatitis B or C. History of a malignancy except for a localized cancer such as skin cancer that is deemed cured. History of myocardial infarction or congestive heart failure. Inability to give informed consent. Current pregnancy.

Sites / Locations

  • Northwestern University, Feinberg School of Medicine

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Hematopoietic Stem Cell Transplantation

Arm Description

Allogeneic Hematopoietic Stem Cell Transplantation will be performed on eligible patients diagnosed with RA

Outcomes

Primary Outcome Measures

Survival
The number of participants who survived treatment

Secondary Outcome Measures

Full Information

First Posted
January 24, 2006
Last Updated
October 24, 2017
Sponsor
Northwestern University
search

1. Study Identification

Unique Protocol Identification Number
NCT00282412
Brief Title
Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism
Official Title
Rheumatoid Arthritis: Tolerance Induction by Mixed Chimerism
Study Type
Interventional

2. Study Status

Record Verification Date
June 2017
Overall Recruitment Status
Terminated
Why Stopped
No participant enrolled for three years. No plan to continue study.
Study Start Date
September 2002 (undefined)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
June 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwestern University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Rheumatoid arthritis disease is believed to be due to immune cells, cells that normally protect the body and are now causing damage to the body. Risk of death is highest in people with twenty or more joints actively involved with disease, positive rheumatoid factor, an elevated sedimentation rate (laboratory measures of active inflammation), and patients with limitation of daily activities (trouble doing simple things like opening a carton of milk). In these high risk patients, life is significantly shortened. Death is usually from heart disease, kidney failure, neck dislocation, broken hip bones, or blood clots to the lung. In this study we use moderate dose chemotherapy (cyclophosphamide and fludarabine) and CAMPATH-1H (a protein that kills the immune cells that are thought to be causing the disease), followed by infusion of blood stem cells that have been collected from the patient's brother or sister (allogeneic stem cell transplant). The purpose of the moderate dose chemotherapy and CAMPATH-1H is to destroy the cells in the immune system and to allow the cells from the patient's brother or sister to grow. The purpose of the stem cell infusion is to restore blood cell production, which will be severely impaired by the moderate dose chemotherapy and CAMPATH-1H, and to produce a normal immune system that will no longer attack the body.
Detailed Description
Peripheral blood stem cell mobilization (PBSC) PBSC will be mobilized with G-CSF (dose may be adjusted down to 5-10 ug/kg/day by PI for toxicity, e.g. flu-like symptoms) with stem cell collection beginning on day 4 or 5. Leukapheresis may be repeated up to four consecutive days. Conditioning Regimen Immune Ablation: Fludarabine 25 mg/m2/d x 5 days (dosage should be based on adjusted body weight) will be given IV over 30 minutes in 100 cc of normal saline. Cyclophosphamide 50 mg/kg/d x 4 days (dosage should be based on adjusted body weight) will be given IV over 1 hour in 500 cc of normal saline. CAMPATH-1H 30 mg/day x 3 days (no dose adjustment) will be given IV over 2 hours in 100 cc of normal saline. Premedication with acetaminophen 650mg & benadryl 25-50mg PO/IV will be given 30-60min before infusion. These medications can be repeated as needed. Hydration approximately 200 cc /hour beginning 6 hours before cyclophosphamide and continued until 24 hours after the last cyclophosphamide dose. G-CSF will be continued until absolute neutrophil count reaches 1,000 cells/ml for three days. Cyclosporine will be started at 200 mg po BID and adjusted by HPLC levels to between 150-250 or by toxicity (e.g. tremor, renal insufficiency, TTP, etc.). CSA will be continued for 6 months unless stopped for toxicity Mycophenolate Mofetil (Cellcept) will be given 1 gram po BID and may be adjusted by toxicity (e.g. cytopenia). Cellcept will be continued for 6 months unless stopped for toxicity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Hematopoietic Stem Cell Transplantation
Arm Type
Experimental
Arm Description
Allogeneic Hematopoietic Stem Cell Transplantation will be performed on eligible patients diagnosed with RA
Intervention Type
Biological
Intervention Name(s)
Hematopoietic Stem Cell Transplantation
Intervention Description
Allogeneic Hematopoietic Stem Cell Transplantation
Intervention Type
Drug
Intervention Name(s)
Fludarabine
Other Intervention Name(s)
Fludara
Intervention Description
inhibits DNA synthesis or repair
Intervention Type
Drug
Intervention Name(s)
Cyclophosphamide
Other Intervention Name(s)
Cytoxan, Neosar
Intervention Description
Causes prevention of cell division by forming adducts with DNA
Intervention Type
Drug
Intervention Name(s)
Campath 1H
Other Intervention Name(s)
Alemtuzumab
Intervention Description
humanized monoclonal antibody against CD52 antigen
Intervention Type
Drug
Intervention Name(s)
GCSF
Other Intervention Name(s)
Neupogen
Intervention Description
Hematopoietic growth factor
Intervention Type
Drug
Intervention Name(s)
Cyclosporins
Other Intervention Name(s)
CSA
Intervention Description
immune suppressive drug
Intervention Type
Drug
Intervention Name(s)
Mycophenolate Mofetil
Other Intervention Name(s)
Cellcept
Intervention Description
immune suppressive drug
Primary Outcome Measure Information:
Title
Survival
Description
The number of participants who survived treatment
Time Frame
up to 5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Participant Inclusion Criteria: Age > 18 and < 60 years at time of pre-transplant evaluation. An established clinical diagnosis of rheumatoid arthritis by American College of Rheumatology criteria. Patients must have failed an autologous hematopoietic transplant or have failed to respond to either methotrexate or leflunomide in combination with a TNF inhibitor. Failure is defined as an inability to tolerate treatment with at least 6 swollen joints and 20 involved joints or inability to answer at least 70% of HAQ questions with "no difficulty" despite 2 or more months of treatment. Ability to give informed consent. Patient must have a HLA matched sibling donor at the A, B, C, and DR loci to proceed or HLA matched cord blood donor. If donor is HLA matched cord blood, cord blood stem cells will be obtained from the NMDP (1-800-548-1375) and one or two units of HLA matched cord blood will be infused on day zero. Participant Exclusion Criteria History of coronary artery disease, or documented congestive heart failure. HIV positive. Uncontrolled diabetes mellitus, or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemoradiotherapy. Prior history of malignancy except localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage I breast cancer will be considered on an individual basis. Positive pregnancy test, inability or unwillingness to pursue effective means of birth control, failure to willingly accept or comprehend irreversible sterility as a side effect of therapy. Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible. FEV1/FVC < 70% of predicted, DLCO < 40% of predicted. Resting LVEF < 45 %. Bilirubin > 2.0 mg/dl (unless due to Gilberts), transferase (AST) > 2.5 x upper limit of normal. Serum creatinine > 2.0 mg/dl. Donor Exclusion Criteria Age < 18 years. Positive for HIV-1, HIV-2, HTLV-I, HTLV-II. Active hepatitis B or C. History of a malignancy except for a localized cancer such as skin cancer that is deemed cured. History of myocardial infarction or congestive heart failure. Inability to give informed consent. Current pregnancy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Burt, MD
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Northwestern University, Feinberg School of Medicine
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

We'll reach out to this number within 24 hrs